Conference Coverage

Bleeding episodes more common in boys with VWD


 

REPORTING FROM THSNA 2018


Multivariate regression analysis revealed independent associations between the following patient characteristics and ever having a bleed among children with type 1 VWD: male gender (adjusted odds ratio, 1.23); being aged 7-9 years at registration, compared with being aged 2-6 years (aOR, 1.5); being black (aOR, 1.7); being Asian, Native Hawaiian or Pacific Islander (aOR, 2.4), being Hispanic (aOR, 2.8), and being some other race/ethnicity (aOR, 1.8). However, family history of a bleeding disorder was protective (aOR, 0.721).

Dr. Abe said she hopes that the findings will raise awareness and help physicians to educate families about bleeding symptoms and intervene to treat bleeding episodes appropriately. She and her associates are planning to compare the data with Community Counts, “so it’s more up to date,” she said.

Dr. Abe reported having no financial disclosures.

SOURCE: Abe K et al. THSNA 2018, Poster 145.

Pages

Recommended Reading

FDA advisory committee supports L-glutamine for SCD
MDedge Pediatrics
FDA approves Rebinyn for hemophilia B treatment
MDedge Pediatrics
Prophylactic emicizumab cut bleeds by 87% in hemophilia A with inhibitors
MDedge Pediatrics
Monthly fitusiran showed promise in small phase I hemophilia trial
MDedge Pediatrics
Vaccination does not eliminate risk for meningococcal disease in eculizumab recipients
MDedge Pediatrics
Allele-matching in cord blood transplant yields better survival
MDedge Pediatrics
HAVEN 2: Emicizumab represents new standard of care for hemophilia A with inhibitors
MDedge Pediatrics
FDA grants breakthrough therapy designation for severe aplastic anemia drug
MDedge Pediatrics
States strive to curb costs for a crucial – but exorbitant – hemophilia treatment
MDedge Pediatrics
Of ‘miracles’ and money: Why hemophilia drugs are so expensive
MDedge Pediatrics